Science and Research

Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial

BACKGROUND: Patients with pulmonary arterial hypertension who achieve a six-minute walk distance of 380-440 m may have improved prognosis. Using the randomized controlled trial of macitentan in pulmonary arterial hypertension (SERAPHIN), the association between six-minute walk distance and long-term outcomes was explored. METHODS: Patients with six-minute walk distance data at Month 6 were dichotomized as above or below the median six-minute walk distance (400 m) and assessed for future risk of pulmonary arterial hypertension-related death or hospitalization and all-cause death. Additionally, six-minute walk distance values at baseline, Month 6 and the change from baseline to Month 6 were categorized by quartiles. All associations were analyzed by the Kaplan-Meier method using a log-rank test and Cox regression models. RESULTS: Patients with a six-minute walk distance >400 m vs. 430 m) vs. Q1 (455 m) vs. Q1 (400 m had better long-term prognosis. Although changes in six-minute walk distance were not associated with long-term outcomes, assessing absolute six-minute walk distance values remains important in the clinical management of patients with pulmonary arterial hypertension.

  • Souza, R.
  • Channick, R. N.
  • Delcroix, M.
  • Galie, N.
  • Ghofrani, H. A.
  • Jansa, P.
  • Le Brun, F. O.
  • Mehta, S.
  • Perchenet, L.
  • Pulido, T.
  • Sastry, B. K. S.
  • Sitbon, O.
  • Torbicki, A.
  • Rubin, L. J.
  • Simonneau, G.

Keywords

  • Adult
  • Female
  • Humans
  • Hypertension, Pulmonary/*diagnosis/physiopathology
  • Male
  • Middle Aged
  • Prognosis
  • *Walking
Publication details
DOI: 10.1371/journal.pone.0193226
Journal: PloS one
Pages: e0193226 
Number: 3
Work Type: Original
Location: UGMLC
Disease Area: PH
Partner / Member: JLU
Access-Number: 29590122
See publication on PubMed

DZL Engagements

chevron-down